NEW MJ NEWS

AbbVie to Present at the Wolfe Research Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 8:30 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-wolfe-research-healthcare-conference-301420573.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$ERBB ZaZZZ Vending Machine Makes History Today

American Green’s ZaZZZ Vending Machine Makes History Today First Customer in the…

$LXRP Updates Sales Channels Efforts

Lexaria Updates Sales Channels Efforts  Lexaria, Corp. (LXRP) (CSE:LXX) (the “Company”) provides…

High Tide Inc. (HITI) Announces Appointment of New Chief Technology Officer

High Tide Announces Appointment of New Chief Technology Officer and Provides Timing…

$OXIS Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer

Oxis Biotech Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer…